1. Home
  2. RMBI vs GANX Comparison

RMBI vs GANX Comparison

Compare RMBI & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Richmond Mutual Bancorporation Inc.

RMBI

Richmond Mutual Bancorporation Inc.

N/A

Current Price

$13.25

Market Cap

132.1M

Sector

Finance

ML Signal

N/A

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$2.63

Market Cap

112.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMBI
GANX
Founded
1887
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.1M
112.7M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
RMBI
GANX
Price
$13.25
$2.63
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.20
AVG Volume (30 Days)
17.4K
683.2K
Earning Date
04-23-2026
01-01-0001
Dividend Yield
4.51%
N/A
EPS Growth
1.10
47.95
EPS
0.82
N/A
Revenue
N/A
$55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$16.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.80
$1.41
52 Week High
$15.24
$4.34

Technical Indicators

Market Signals
Indicator
RMBI
GANX
Relative Strength Index (RSI) 35.15 54.52
Support Level $13.02 $2.60
Resistance Level $14.31 $2.79
Average True Range (ATR) 0.37 0.22
MACD -0.06 -0.01
Stochastic Oscillator 15.33 36.88

Price Performance

Historical Comparison
RMBI
GANX

About RMBI Richmond Mutual Bancorporation Inc.

Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: